Publicaciones (106) Publicaciones de DAVID OTAEGUI BICHOT

2024

  1. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 11, Núm. 4, pp. e200270

  2. Bacteria–Fungi Interactions in Multiple Sclerosis

    Microorganisms, Vol. 12, Núm. 5

  3. Centenarian hippocampus displays high levels of astrocytic metallothioneins

    Aging Cell, Vol. 23, Núm. 8

  4. Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers?

    Translational Neurodegeneration, Vol. 13, Núm. 1

  5. Microbiota modulation by teriflunomide therapy in people with multiple sclerosis: An observational case-control study

    Neurotherapeutics

  6. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Blood RNA-Seq profiling reveals a set of circular RNAs differentially expressed in frail individuals

    Immunity and Ageing, Vol. 20, Núm. 1

  2. Early biochemical analysis of COVID-19 patients helps severity prediction

    PLoS ONE, Vol. 18, Núm. 5 May

  3. Editorial: Innovative OMICs-technology applications to reach a diagnosis and bring new therapies to immune-mediated neurological diseases

    Frontiers in Immunology

  4. Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection

    Frontiers in Aging, Vol. 4

  5. Zahartzea, ikerketa medikoen ikuspegitik

    Elhuyar: zientzia eta teknika, Núm. 352, pp. 28-33

2022

  1. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course

    Cell, Vol. 185, Núm. 19, pp. 3467-3486.e16

  2. Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis

    Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163

  3. Microbial dysbiosis and lack of SCFA production in a Spanish cohort of patients with multiple sclerosis

    Frontiers in Immunology, Vol. 13

  4. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

    Journal of Neuroinflammation, Vol. 19, Núm. 1

  5. The innovative animal monitoring device for experimental autoimmune encephalomyelitis (“I AM D EAE”): A more detailed evaluation for improved results

    Multiple Sclerosis and Related Disorders, Vol. 63

2021

  1. Assessing the potential of molecular imaging for myelin quantification in organotypic cultures

    Pharmaceutics, Vol. 13, Núm. 7

  2. Extracellular vesicles in blood: Sources, effects and applications

    International Journal of Molecular Sciences, Vol. 22, Núm. 15

  3. Gut microbiota changes in experimental autoimmune encephalomyelitis and cuprizone mice models

    ACS Chemical Neuroscience, Vol. 12, Núm. 5, pp. 893-905

  4. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 3, pp. 366-379